Regarding glycolytic enzymes, inhibiting key enzymes in the glycolytic pathway, such as hexokinase 2 (HK2) or pyruvate kinase M2 (PKM2), can reduce the glycolytic flux and limit the availability of metabolic intermediates necessary for tumor survival. This evidence concerns the gene PKM and neoplasm.